Table 1 Patients’ demographical and oncological data (n = 90)
Item | Mean value | Minimum value | Maximum value | Remarks |
|---|---|---|---|---|
Age | 56.97 | 21.1 | 84.0 | Years |
Karnofsky performance status | 78% | 50% | 100% | |
Follow-up | 3.5 | 0 | 12.25 | Years |
Item | Value (%) | |||
T-stage | ||||
T1 | 14 (16%) | |||
T2 | 33 (37%) | |||
T3 | 8 (9%) | |||
T4 | 35 (38%) | |||
N-stage | ||||
N0 | 20 (22%) | |||
N1 | 24 (27%) | |||
N2 | 46 (51%) | |||
N3 | 0 | |||
UICC stage | ||||
I | 7 (8%) | |||
II | 6 (7%) | |||
III | 11 (12%) | |||
IV | 66 (73%) | |||
Pre-treatment | ||||
None | 27 (30%) | |||
Surgery | 61 (70%) | |||
Surgery to the lower jaw | ||||
Partial resection | 16 (23%) | |||
Continuity resection | 10 (14%) | |||
Chemotherapy | 17 (19%) | |||
Radiotherapy – fractionation | ||||
Conventional | 74 (82%) | |||
Hyperfractionation | 16 (18%) | |||
Fraction size | Gy/day | |||
1 × 2.0 | 72 (80%) | |||
1 × 3.0 | 2 (2%) | |||
2 × 1.2 | 15 (17%) | |||
2 × 1.4 | 1 (1%) | |||
total dose – conventionally fractionated (n = 75) | Gy | |||
30 | 1 (1%) | |||
36 | 1 (1%) | |||
50 | 7 (9%) | |||
58 | 2 (2%) | |||
60 | 31 (44%) | |||
64 | 9 (13%) | |||
70 | 23 (31%) | |||
Total dose – hyperfractionated (n = 15) | ||||
58.8 | 1 (6%) | |||
70.8 | 1 (6%) | |||
72.0 | 12 (76%) | |||
72.8 | 1 (6%) | |||
76.8 | 1 (6%) | |||